• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002020.SZ
Share

Zhejiang Jingxin Pharmaceutical Co., Ltd. Stocks

CN¥ 14.02Last Updated 14.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.82B

CN¥ 14.02
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhejiang Jingxin Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the full spectrum of pharmaceutical activities, from research and development to manufacturing and sales within the country. Its diverse product line includes active pharmaceutical ingredients (APIs), along with a wide array of finished medications such as antihypertensives, various antibiotics (including quinolones and cephalosporins), gastrointestinal remedies, antidiabetics, antipileptics, antihistamines, H+ pump inhibitors, H2 receptor blockers, cholesterol-lowering drugs, and antidepressants, as well as biopharmaceutical products. Additionally, the company is a provider of advanced medical display solutions, offering diagnostic, surgical, clinical, large-screen, integrated, and ultrasonic medical displays. Originally founded in 1974 as Zhejiang Jingxin Pharmaceutical Factory, the company officially rebranded to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000 and maintains its headquarters in Xinchang, China.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 002020.SZ is 16.0 and suggests 11.7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 12:58

Following SK Hynix, Samsung has approved the listing of its securities in the U.S. — Bloomberg

14.07.2026 12:20

DeepSeek Founder Is Now the Richest AI Model Developer — Bloomberg

14.07.2026 11:10

Oil prices soared to a one-month high following new attacks by the U.S. and Iran in the Strait of Hormuz

14.07.2026 10:44

Intraday volatility: SK Hynix shares rebounded after a 9% plunge

14.07.2026 10:38

Morning Highlights: Oil Prices Rise Amid Strikes on Iran; Nvidia Tightens Export Controls

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026